Angry mum shares picture of free school meal food parcel as Marcus Rashford says it s unacceptable chroniclelive.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from chroniclelive.co.uk Daily Mail and Mail on Sunday newspapers.
RTW Participates in $75 Million Financing Round in Immunocore
RTW Venture Fund Limited (the Company ), the London Stock Exchange-listed investment company focused on identifying transformative assets with high growth potential across the life sciences sector, is pleased to note the announcement by its portfolio company Immunocore, Ltd ( Immunocore ) on 11 January 2021 of its completion of a $75 million Series C financing round. The announcement of the financing round comes following positive Phase 3 trial interim analysis data for tebentafusp in patients with metastatic uveal melanoma that Immunocore presented in December 2020.
The Company, alongside other investment vehicles of RTW Investments, LP (the Investment Manager ), confirms that it participated in the financing round together with other investment firms.
As the country gears up to carry out two million vaccinations a week, you could be forgiven for thinking that investing in healthcare might be a smart move right now.
But while it s true that the extraordinary scientific advances of the last year have rightly made superstars out of women and men in white coats – the likes of Oxford University s Sarah Gilbert and BioNTech founders Ugur Sahin and Ozlem Tureci – it hasn t necessarily given a shot in the arm to those who have bought into big pharmaceutical businesses.
The sector was a standout performer in the first half of 2020, but it underperformed in the second, particularly in the UK.
RTW Participates in $56 Million Financing Round in Biomea Fusion
RTW Venture Fund Limited (the Company ), the London Stock Exchange-listed investment company focused on identifying transformative assets with high growth potential across the life sciences sector, is pleased to note the announcement by Biomea Fusion, Inc. ( Biomea ) on 06 January 2021 of its completion of a $56 million Series A financing round.
The Company, alongside other investment vehicles of RTW Investments, LP (the Investment Manager ), confirms that it participated in the financing round together with other investment firms.
Biomea is a US-based privately held precision oncology company dedicated to developing innovative medicines targeting specific cancer driving mutations. Biomea plans to use the proceeds from the financing round to advance the development of its portfolio of irreversible inhibitors, including a potentially first-in-class irreversible inhibitor of menin, a key newly recognized onco-target
A
Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient: 1. Obtains access to the information in a personal capacity; 2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services; 3. Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body; 4. Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;